Phase I/II Study of Low-Dose Cyclophosphamide, Tumor Associated Peptide Antigen-Pulsed Dendritic Cell Therapy and Low Dose GM-CSF, in Patients With Progressive and/or Refractory Hematologic Malignancies
Phase of Trial: Phase I/II
Latest Information Update: 17 Aug 2017
At a glance
- Drugs KiroVAX 002 (Primary) ; KiroVAX 002 (Primary) ; Cyclophosphamide; Granulocyte macrophage colony stimulating factor
- Indications Chronic lymphocytic leukaemia; Haematological malignancies; Hodgkin's disease; Multiple myeloma; Non-Hodgkin's lymphoma
- Focus Adverse reactions
- Sponsors Kiromic
- 01 Aug 2017 Planned End Date changed from 1 Sep 2017 to 31 Jan 2019.
- 01 Aug 2017 Planned primary completion date changed from 1 May 2017 to 31 Oct 2018.
- 01 Aug 2017 Status changed from not yet recruiting to recruiting.